NDA 019888 · Almatica
Zestoretic
Hydrochlorothiazide, Lisinopril · Oral · Thiazide Diuretic
Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Jul 20, 1989
Approved uses
2
Original approval plus efficacy supplements
Registered trials
450
138 Phase 3, 14 recruiting
FAERS reports
10,267
6,201 serious, 596 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue ZESTORETIC as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity.
What it is approved for
From the label in effect Mar 31, 2025.
INDICATIONS AND USAGE ZESTORETIC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 18, 1993 Supplement 11 · Efficacy
- Jul 20, 1989 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- ZESTORETIC · HYDROCHLOROTHIAZIDE 12.5MG; LISINOPRIL 10MG · TABLET, ORAL · Prescription · TE AB
- ZESTORETIC · HYDROCHLOROTHIAZIDE 12.5MG; LISINOPRIL 20MG · TABLET, ORAL · Prescription · TE AB
- ZESTORETIC · HYDROCHLOROTHIAZIDE 25MG; LISINOPRIL 20MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.
- INVEST: INternational VErapamil SR Trandolapril STudyPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT00133692 · 22,000 participants · Start Sep 1997
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Atenolol/HCTZ/Trandolapril · For: Hypertension; Coronary Artery Disease
Sites: Gainesville, Florida
- Diuretic Comparison ProjectPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT02185417 · 20,723 participants · Start Jun 15, 2016 · Primary completion Oct 15, 2022
Drug: Hydrochlorothiazide (HCTZ); Chlorthalidone (CTD) · For: Hypertension
Sites: Birmingham, Alabama; Anchorage, Alaska; Fayetteville, Arkansas · 70 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01271985 · 8,410 participants · Start Feb 2011 · Primary completion Jan 2019
Drug: PolyPill · For: Cardiovascular Diseases
Sites: Gonbad, Iran
- Strategy of Blood Pressure Intervention in the Elderly Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT03015311 · 8,000 participants (planned) · Start Jan 15, 2017 · Primary completion Dec 31, 2020
Drug: Intensive BP control; Standard BP control · For: Primary Hypertension
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 42 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea692
- fatigue684
- diarrhoea618
- drug ineffective577
- pain505
- dizziness498
- dyspnoea444
- headache438
- asthenia372
- vomiting357
- cough354
- arthralgia341
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 174 |
| 2005 | 178 |
| 2006 | 210 |
| 2007 | 230 |
| 2008 | 312 |
| 2009 | 501 |
| 2010 | 786 |
| 2011 | 771 |
| 2012 | 726 |
| 2013 | 175 |
| 2014 | 440 |
| 2015 | 833 |
| 2016 | 581 |
| 2017 | 430 |
| 2018 | 553 |
| 2019 | 474 |
| 2020 | 530 |
| 2021 | 449 |
| 2022 | 417 |
| 2023 | 410 |
| 2024 | 355 |
| 2025 | 440 |
| 2026 | 292 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zestoretic (Lisinopril/Hydrochlorothiazide)
2024 spending
$696K
Beneficiaries
183
659 claims
Per beneficiary
$3,805
$12.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,306,300 |
| 2021 | $1,175,166 |
| 2022 | $1,044,872 |
| 2023 | $882,756 |
| 2024 | $696,348 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Ishani A, Cushman WC, Leatherman SM, et al. · N Engl J Med 2022 · Comparative Study, Pragmatic Clinical Trial
- Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
Dhayat NA, Bonny O, Roth B, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.
Roush GC, Ernst ME, Kostis JB, et al. · Hypertension 2015 · Meta-Analysis, Systematic Review
- Oslo Hypertension Study.
Leren P, Helgeland A · Drugs 1986 · Clinical Trial, Randomized Controlled Trial
- Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K, Weber MA, Bakris GL, et al. · N Engl J Med 2008 · Comparative Study, Multicenter Study
- Antihypertensive treatment effect of two dual therapies according to sodium sensitivity.
Huang QF, Zhang D, Luo Y, et al. · Hypertens Res 2026 · Randomized Controlled Trial, Multicenter Study
Sponsor: Almatica
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.